In a proactive move, the company has engaged Grant Thornton LLP as its new independent registered public accounting firm, effective March 26, 2026. This transition is expected to enhance the company's financial oversight and reporting processes. The decision to change auditors reflects a strategic approach to governance and operational execution, aiming to bolster investor confidence and ensure compliance with regulatory standards. The company has indicated that it will continue to address the previously identified material weakness in its internal controls, working closely with Grant Thornton to improve its financial reporting framework. Overall, these changes are seen as part of OptimizeRx's commitment to maintaining high standards of governance and operational integrity.
2026-03-30 21:31:55
OptimizeRx Corporation Dismisses UHY LLP as Independent Auditor, Appoints Grant Thornton LLP
Expected Stock impact: None Expected
On March 30, 2026, OptimizeRx Corporation filed an 8-K report detailing significant changes in its auditing arrangements. The Audit Committee of the Board of Directors approved the dismissal of UHY LLP as the company's independent registered public accounting firm, effective immediately. This decision was made following a review of UHY's audit reports for the fiscal years ending December 31, 2025, and 2024, which did not contain any adverse opinions or disclaimers. Notably, there were no disagreements with UHY regarding accounting principles or practices during this period. However, the company had previously disclosed a material weakness in internal control over financial reporting related to data received from third-party service organizations. This weakness did not result in any restatement of financial statements and was discussed with UHY prior to their dismissal.
In a proactive move, the company has engaged Grant Thornton LLP as its new independent registered public accounting firm, effective March 26, 2026. This transition is expected to enhance the company's financial oversight and reporting processes. The decision to change auditors reflects a strategic approach to governance and operational execution, aiming to bolster investor confidence and ensure compliance with regulatory standards. The company has indicated that it will continue to address the previously identified material weakness in its internal controls, working closely with Grant Thornton to improve its financial reporting framework. Overall, these changes are seen as part of OptimizeRx's commitment to maintaining high standards of governance and operational integrity.
In a proactive move, the company has engaged Grant Thornton LLP as its new independent registered public accounting firm, effective March 26, 2026. This transition is expected to enhance the company's financial oversight and reporting processes. The decision to change auditors reflects a strategic approach to governance and operational execution, aiming to bolster investor confidence and ensure compliance with regulatory standards. The company has indicated that it will continue to address the previously identified material weakness in its internal controls, working closely with Grant Thornton to improve its financial reporting framework. Overall, these changes are seen as part of OptimizeRx's commitment to maintaining high standards of governance and operational integrity.
